Skip to main content
Investor Center

New Release – Imagin Medical Grants Stock Options

By 10 April 2017August 26th, 2021No Comments

Vancouver, B.C. and Boston, MA, April 10, 2017 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the “Company”) announced today that pursuant to the Company’s Stock Option Plan, an aggregate of 300,000 shares have been granted to a consultant as incentive stock options at an exercise price of $0.12 per share. The options are exercisable for a period of five years, ending on April 10, 2022. 

About Imagin Medical 

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com. 

ON BEHALF OF THE BOARD: 

Jim Hutchens,
President & CEO 

For further information, contact: 

Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: [email protected] 

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.